Dec 10, 2021 / 01:30PM GMT
Operator
Good morning, ladies and gentlemen, and welcome to the Arvinas and Pfizer conference call. (Operator Instructions)
I would now like to turn the call over to Jeff Boyle, Vice President, Investor Relations at Arvinas. Please proceed.
Jeff Boyle - Arvinas, Inc. - VP of IR
Thank you, operator. Good morning, everyone, and thank you for joining us to discuss the ARV-471 dose escalation clinical trial results presented this morning at San Antonio Breast Cancer Symposium. Earlier this morning, we issued a press release highlighting these data, which can be accessed in the Investors section of our website at arvinas.com.
With me today are Arvinas President and Chief Executive Officer, John Houston; Arvinas Chief Medical Officer, Ron Peck; and Pfizer Oncology Chief Development Officer, Chris Boshoff. Ian Taylor, our Chief Scientific Officer, will join for the Q&A portion of the call.
Before we begin the call, I'd like to remind you that today's discussion will contain forward-looking statements that involve risks and uncertainties. These
Pfizer Inc to Discuss Updated Phase 1 Dose Escalation Data for ARV-471 Call Transcript
Dec 10, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers